Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Single-center, Phase I Proof of Concept Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis

NCT02912897 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT02912897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02912897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Single-center, Phase I Proof of Concept Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis
Lead sponsor
Nantes University Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
January 26, 2021
Completion date
November 30, 2028
Enrollment
7 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis